Our DMPK group has developed a comprehensive set of assays to characterize and assess the drug-like properties of project compounds. To select the best candidates for advancement, we optimize the structural properties to improve clinical pharmacokinetic (PK) outcomes, providing quick turnaround of data to speed compound progression. We also leverage state-of-the-art platforms such as liquid chromatography/mass spectrometry (LC/MS) to reliably identify and quantitate solutions for your most complex molecular challenges.
We offer the following assays:
SELECTED ASSAYS FOR GUIDING COMPOUND PROGRESSION | |||
| Hit to Lead | Lead Optimization | Candidate Selection | IND-Enabling |
|---|---|---|---|
| Solubility | Plasma protein binding | Reactive metabolites | CYP inhibition |
| PAMPA permeability | CYP inhibition-LC/MS/MS | hERG inhibition | CYP induction |
| Metabolic stability/clearance | Cell-based permeability: MDR1-MDCK, Caco-2 | Non-GLP Ames test | CYP reaction phenotyping |
| CYP inhibition, fluorescence | Metabolite profiling and ID | In vivo metabolite ID | Species comparison of metabolic pathways |
| Chemical stability | In vivo PK and bioanalysis | Hepatocyte metabolic clearance | |
| Plasma stability | Cytotoxicity | ||